2 results
Approved WMOWill not start
Primary: To evaluate the efficacy of once-weekly lonapegsomatropin compared to placebo at 38 weeks in adults with growth hormone deficiency (GHD). Secondary: 1. To evaluate the safety and tolerability of once-weekly lonapegsomatropin in adults with…
Approved WMORecruiting
TEMPO will directly compare i) conventional 2-step reduction with ii) gradual tapering in patients with remitted MDD who use either the antidepressant paroxetine (PAR) or venlafaxine (VLX). We will evaluate the number of patients that can…